161 related articles for article (PubMed ID: 35326705)
1. CDK6 Degradation Is Counteracted by p16
Schmalzbauer BS; Thondanpallil T; Heller G; Schirripa A; Sperl CM; Mayer IM; Knab VM; Nebenfuehr S; Zojer M; Mueller AC; Fontaine F; Klampfl T; Sexl V; Kollmann K
Cancers (Basel); 2022 Mar; 14(6):. PubMed ID: 35326705
[TBL] [Abstract][Full Text] [Related]
2. Expression of p16Ink4a compensates for p18Ink4c loss in cyclin-dependent kinase 4/6-dependent tumors and tissues.
Ramsey MR; Krishnamurthy J; Pei XH; Torrice C; Lin W; Carrasco DR; Ligon KL; Xiong Y; Sharpless NE
Cancer Res; 2007 May; 67(10):4732-41. PubMed ID: 17510401
[TBL] [Abstract][Full Text] [Related]
3. Altered expression of G1/S phase cell cycle regulators in placental mesenchymal stromal cells derived from preeclamptic pregnancies with fetal-placental compromise.
Nuzzo AM; Giuffrida D; Masturzo B; Mele P; Piccoli E; Eva C; Todros T; Rolfo A
Cell Cycle; 2017 Jan; 16(2):200-212. PubMed ID: 27937072
[TBL] [Abstract][Full Text] [Related]
4. Structure of human cyclin-dependent kinase inhibitor p19INK4d: comparison to known ankyrin-repeat-containing structures and implications for the dysfunction of tumor suppressor p16INK4a.
Baumgartner R; Fernandez-Catalan C; Winoto A; Huber R; Engh RA; Holak TA
Structure; 1998 Oct; 6(10):1279-90. PubMed ID: 9782052
[TBL] [Abstract][Full Text] [Related]
5. Cyclin D-CDK subunit arrangement is dependent on the availability of competing INK4 and p21 class inhibitors.
Parry D; Mahony D; Wills K; Lees E
Mol Cell Biol; 1999 Mar; 19(3):1775-83. PubMed ID: 10022865
[TBL] [Abstract][Full Text] [Related]
6. Differential post-transcriptional regulation of two Ink4 proteins, p18 Ink4c and p19 Ink4d.
Forget A; Ayrault O; den Besten W; Kuo ML; Sherr CJ; Roussel MF
Cell Cycle; 2008 Dec; 7(23):3737-46. PubMed ID: 19029828
[TBL] [Abstract][Full Text] [Related]
7. Tumor suppressor INK4: comparisons of conformational properties between p16(INK4A) and p18(INK4C).
Yuan C; Li J; Selby TL; Byeon IJ; Tsai MD
J Mol Biol; 1999 Nov; 294(1):201-11. PubMed ID: 10556039
[TBL] [Abstract][Full Text] [Related]
8. Contrasting behavior of the p18INK4c and p16INK4a tumor suppressors in both replicative and oncogene-induced senescence.
Gagrica S; Brookes S; Anderton E; Rowe J; Peters G
Cancer Res; 2012 Jan; 72(1):165-75. PubMed ID: 22080569
[TBL] [Abstract][Full Text] [Related]
9. Biochemical characterization of p16INK4- and p18-containing complexes in human cell lines.
Ragione FD; Russo GL; Oliva A; Mercurio C; Mastropietro S; Pietra VD; Zappia V
J Biol Chem; 1996 Jul; 271(27):15942-9. PubMed ID: 8663131
[TBL] [Abstract][Full Text] [Related]
10. INK4 Tumor Suppressor Proteins Mediate Resistance to CDK4/6 Kinase Inhibitors.
Li Q; Jiang B; Guo J; Shao H; Del Priore IS; Chang Q; Kudo R; Li Z; Razavi P; Liu B; Boghossian AS; Rees MG; Ronan MM; Roth JA; Donovan KA; Palafox M; Reis-Filho JS; de Stanchina E; Fischer ES; Rosen N; Serra V; Koff A; Chodera JD; Gray NS; Chandarlapaty S
Cancer Discov; 2022 Feb; 12(2):356-371. PubMed ID: 34544752
[TBL] [Abstract][Full Text] [Related]
11. An important role of CDK inhibitor p18(INK4c) in modulating antigen receptor-mediated T cell proliferation.
Kovalev GI; Franklin DS; Coffield VM; Xiong Y; Su L
J Immunol; 2001 Sep; 167(6):3285-92. PubMed ID: 11544316
[TBL] [Abstract][Full Text] [Related]
12. p16-Cdk4-Rb axis controls sensitivity to a cyclin-dependent kinase inhibitor PD0332991 in glioblastoma xenograft cells.
Cen L; Carlson BL; Schroeder MA; Ostrem JL; Kitange GJ; Mladek AC; Fink SR; Decker PA; Wu W; Kim JS; Waldman T; Jenkins RB; Sarkaria JN
Neuro Oncol; 2012 Jul; 14(7):870-81. PubMed ID: 22711607
[TBL] [Abstract][Full Text] [Related]
13. Growth suppression by p18, a p16INK4/MTS1- and p14INK4B/MTS2-related CDK6 inhibitor, correlates with wild-type pRb function.
Guan KL; Jenkins CW; Li Y; Nichols MA; Wu X; O'Keefe CL; Matera AG; Xiong Y
Genes Dev; 1994 Dec; 8(24):2939-52. PubMed ID: 8001816
[TBL] [Abstract][Full Text] [Related]
14. Feedback circuit among INK4 tumor suppressors constrains human glioblastoma development.
Wiedemeyer R; Brennan C; Heffernan TP; Xiao Y; Mahoney J; Protopopov A; Zheng H; Bignell G; Furnari F; Cavenee WK; Hahn WC; Ichimura K; Collins VP; Chu GC; Stratton MR; Ligon KL; Futreal PA; Chin L
Cancer Cell; 2008 Apr; 13(4):355-64. PubMed ID: 18394558
[TBL] [Abstract][Full Text] [Related]
15. Structural basis of inhibition of CDK-cyclin complexes by INK4 inhibitors.
Jeffrey PD; Tong L; Pavletich NP
Genes Dev; 2000 Dec; 14(24):3115-25. PubMed ID: 11124804
[TBL] [Abstract][Full Text] [Related]
16. Identification of functional elements of p18INK4C essential for binding and inhibition of cyclin-dependent kinase (CDK) 4 and CDK6.
Noh SJ; Li Y; Xiong Y; Guan KL
Cancer Res; 1999 Feb; 59(3):558-64. PubMed ID: 9973200
[TBL] [Abstract][Full Text] [Related]
17. Cdk4 and Cdk6 cooperate in counteracting the INK4 family of inhibitors during murine leukemogenesis.
Rodríguez-Díez E; Quereda V; Bellutti F; Prchal-Murphy M; Partida D; Eguren M; Kollmann K; Gómez de Cedrón M; Dubus P; Cañamero M; Martínez D; Sexl V; Malumbres M
Blood; 2014 Oct; 124(15):2380-90. PubMed ID: 25157181
[TBL] [Abstract][Full Text] [Related]
18. Limited overlapping roles of P15(INK4b) and P18(INK4c) cell cycle inhibitors in proliferation and tumorigenesis.
Latres E; Malumbres M; Sotillo R; Martín J; Ortega S; Martín-Caballero J; Flores JM; Cordón-Cardo C; Barbacid M
EMBO J; 2000 Jul; 19(13):3496-506. PubMed ID: 10880462
[TBL] [Abstract][Full Text] [Related]
19. Structure-based design of p18INK4c proteins with increased thermodynamic stability and cell cycle inhibitory activity.
Venkataramani RN; MacLachlan TK; Chai X; El-Deiry WS; Marmorstein R
J Biol Chem; 2002 Dec; 277(50):48827-33. PubMed ID: 12370184
[TBL] [Abstract][Full Text] [Related]
20. Distinct versus redundant properties among members of the INK4 family of cyclin-dependent kinase inhibitors.
Thullberg M; Bartkova J; Khan S; Hansen K; Rönnstrand L; Lukas J; Strauss M; Bartek J
FEBS Lett; 2000 Mar; 470(2):161-6. PubMed ID: 10734227
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
